Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
Withdrawn before enrolling · Phase 2
Conditions studied: Stage IV Prostate Cancer
In brief
Current therapies for Refractory Stage IV Prostate Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Refractory Stage IV Prostate Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Refractory Stage IV Prostate Cancer.
Key facts
- Study ID
- NCT00003534
- Run by
- Burzynski Research Institute
- People needed
- 0
- Starts
- 1996-10-11
- Expected to finish
- 1997-02-20
- Last updated by the study team
- 2018-01-31
Who can join
Age: 18 and older, up to 99. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Burzynski Clinic — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.